Retrospective chart review (n=891) of adults treated with IV ketamine for MDD, bipolar disorder, PTSD, or OCD at a Canadian clinic to characterise outcomes and safety.
The Canadian Rapid Treatment Centre of Excellence conducted a retrospective analysis of patients treated with intravenous ketamine for primary diagnoses of Major Depressive Disorder, Bipolar Disorder, Post-traumatic Stress Disorder, or Obsessive-Compulsive Disorder to better understand clinical outcomes and safety.
Data cover patients from clinic opening (June 2018) to present; analyses include demographics, diagnosis groups, treatment parameters, response and remission rates, and adverse events recorded in routine clinical care.
DSM-5 diagnosis of Major Depressive Disorder receiving IV ketamine.
Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol.
DSM-5 diagnosis of Bipolar Disorder receiving IV ketamine.
Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol.
DSM-5 diagnosis of Obsessive-Compulsive Disorder receiving IV ketamine.
Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol.
DSM-5 diagnosis of Post-traumatic Stress Disorder receiving IV ketamine.
Ketamine Hydrochloride (racemic); subanesthetic IV infusions per local protocol.
This retrospective analysis (n=100) of the effectiveness of ketamine (35mg/70kg) for borderline personality disorder (BPD) in those with treatment-resistant depression (TRD) finds that intravenous ketamine significantly reduces symptoms of depression, borderline personality, suicidality, and anxiety in patients with comorbid BPD and TRD. Both BPD-positive and BPD-negative groups showed significant improvements in the primary outcome measures, with no significant difference between groups.